Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07157033 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.
A Phase 1 study of Locally Advanced Pancreatic Adenocarcinoma and Locally Advanced Pancreatic Ductal Adenocarcinoma, sponsored by Xerient Pharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 2
- Study locations
NCT07157033 is a Phase 1 study of Locally Advanced Pancreatic Adenocarcinoma and Locally Advanced Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by Xerient Pharma. The registered enrollment target is 36 participants, below the 65-participant average among 18 other Locally Advanced Pancreatic Adenocarcinoma trials with a reported enrollment target (45% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT07157033, a Phase 1 study of Locally Advanced Pancreatic Adenocarcinoma and Locally Advanced Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by Xerient Pharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to assess the safety, tolerability and efficacy of XER-001 and identify a best dose for future studies.
Conditions Studied
Interventions
- DRUG XER-001
Study Locations (2)
New Mexico
- Christus St. Vincent Regional Cancer Center - Santa Fe
Texas
- Oncology Consultants, P.A. - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2026-01-01 |
| Est. Completion | 2034-07-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07157033
The ClinicalTrials.gov registry entry for NCT07157033 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 65-participant average among 18 other Locally Advanced Pancreatic Adenocarcinoma trials with a reported enrollment target (45% lower). The listed sponsor is Xerient Pharma, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Locally Advanced Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which XER-001 is the first listed.
NCT07157033 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New Mexico, Texas.
Frequently Asked Questions
What is clinical trial NCT07157033 about?
NCT07157033 is a clinical study titled "A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.". The purpose of this study is to assess the safety, tolerability and efficacy of XER-001 and identify a best dose for future studies.
What is the current status of trial NCT07157033?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2026-01-01. Estimated completion is 2034-07-31.
What conditions does trial NCT07157033 study?
This clinical trial studies the following conditions: Locally Advanced Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreas Cancer.
What interventions are being tested in trial NCT07157033?
The interventions under investigation include: XER-001 (DRUG).
Who is sponsoring clinical trial NCT07157033?
This trial is sponsored by Xerient Pharma, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07157033 being conducted?
This trial has 2 study locations across New Mexico, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced Pancreatic Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 1
-
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
RECRUITING · Phase 1
-
Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma
ACTIVE NOT RECRUITING · Phase 1
-
Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 1
-
BATs Treatment for Pancreatic Cancer, Phase Ib/II
ACTIVE NOT RECRUITING · Phase 1
-
Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Locally Advanced Pancreatic Adenocarcinoma
All registered trials for this condition
Locally Advanced Pancreatic Ductal Adenocarcinoma
All registered trials for this condition
New Mexico
All trials with a study site in New Mexico
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.